Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 20, Issue 3, 2005, Pages 539-544

  Okuyama, Shin ^a   Komatsuda, Atsushi ^a   Wakui, Hideki ^a   Aiba, Namiko ^a   Fujishima, Naohito ^a   Iwamoto, Keiko ^a   Ohtani, Hiroshi ^a   Sawada, Ken Ichi ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene expression profile; Minimal change nephrotic syndrome; Serial analysis of gene expression; Tumour necrosis factor related apoptosis inducing ligand

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; AZATHIOPRINE; CARNITINE ACETYLTRANSFERASE; CYCLINE; CYCLOPHILIN; CYCLOSPORIN A; FK 506 BINDING PROTEIN; GENE PRODUCT; INITIATION FACTOR 1; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOGLUCONATE DEHYDROGENASE; PHOSPHOLIPASE A1; PHOSPHORYLASE KINASE; PREDNISOLONE; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTHYMOSIN ALPHA; SECRETORY PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROPOMYOSIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UVOMORULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ANALYSIS; GLOMERULOPATHY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERIAL ANALYSIS OF GENE EXPRESSION; T LYMPHOCYTE; UPREGULATION;

ADOLESCENT; ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEPHROSIS, LIPOID; REMISSION, SPONTANEOUS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 15044346720     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh673     Document Type: Article

References (20)

1. Falk RJ, Jennette JC, Nachman PH. Primary glomerular diseases: minimal change glomerulopathy. In: Brenner BM, ed. The Kidney, 7th edn. WB Saunders, Philadelphia, PA: 1301-1307
2. Yoshizawa N, Kusumi Y, Matsumoto K et al. Studies of a glomerular permeability factor in patients with minimal-change nephritic syndrome. Nephron 1989; 51: 370-376
3. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40: 453-460
4. Pegoraro AA, Singh AK, Arruda JAL, Dunea G, Bakir AA. A simple method to detect an albumin permeability factor in the idiopathic nephrotic syndrome. Kidney Int 2000; 58: 1342-1345
5. Lama G, Luongo I, Tirino G et al. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis 2002; 39: 958-965
6. Sahali D, Pawlak A, Valanciuté A et al. A novel approach to investigation of the pathogenesis of active minimal-change nephritic syndrome using subtracted cDNA library screening. J Am Soc Nephrol 2002; 13: 1238-1247
7. Ye SQ, Usher DC, Zhang LQ. Gene expression profiling of human diseases by serial analysis of gene expression. J Biomed Sci 2002; 9: 384-394
8. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682
9. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003; 139: 89-97
10. Ichikawa Y, Hirokawa M, Aiba N et al. Monitoring the expression profiles of doxorubicin-resistant K562 human leukemia cells by serial analysis of gene expression. Int J Hematol 2004; 79: 276-282
11. Monlen I, Martinez-Lorenzo MJ, Monteagudo L et al. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 2001; 167: 6736-6744
12. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28: 973-982
13. Matsuyama W, Yamamoto M, Higashimoto I et al. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood 2004; 104: 184-191
14. Wandinger K-P, Lunemann JD, Wengert O et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361: 2036-2043
15. Tecchio C, Huber V, Scapini P et al. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004; 103: 3837-3844
16. Traynor A, Kuzel T, Samuelson E, Wanwar Y. Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma. Nephron 1994; 67: 94-100
17. Nakao K, Sugiyama H, Makino E et al. Minimal-change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma. Nephron 2002; 90: 498-500
18. Nishimura S, Miura H, Yamada H et al. Acute onset of nephrotic syndrome during interferon-α retreatment for chronic active hepatitis C. J Gastroenterol 2002; 37: 854-858
19. Dizer U, Beker CM, Yavuz I et al. Minimal change disease in patient receiving INF-alpha therapy for chronic hepatitis C virus infection. J Interferon Cytokine Res 2003; 23: 51-54
20. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333-339